228 related articles for article (PubMed ID: 23207943)
1. Resectable rectal cancer: which patient does not need preoperative radiotherapy?
Kulu Y; Ulrich A; Büchler MW
Dig Dis; 2012; 30 Suppl 2():118-25. PubMed ID: 23207943
[TBL] [Abstract][Full Text] [Related]
2. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.
Peeters KC; Marijnen CA; Nagtegaal ID; Kranenbarg EK; Putter H; Wiggers T; Rutten H; Pahlman L; Glimelius B; Leer JW; van de Velde CJ;
Ann Surg; 2007 Nov; 246(5):693-701. PubMed ID: 17968156
[TBL] [Abstract][Full Text] [Related]
3. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
4. [The optimult study concept - selective neoadjuvant chemoradiation therapy based on preoperative MRI].
Kreis ME; Junginger T; Rödel C; Heinemann V; Nikolaou K; Mansmann U; Jauch KW
Zentralbl Chir; 2010 Aug; 135(4):302-6. PubMed ID: 20806131
[TBL] [Abstract][Full Text] [Related]
5. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
Thomschke D; Kyau-Ummen B; Halbfass HJ
Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
[TBL] [Abstract][Full Text] [Related]
6. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
7. The effect of circumferential tumor location in clinical outcomes of rectal cancer patients treated with total mesorectal excision.
Lee SH; Hernandez de Anda E; Finne CO; Madoff RD; Garcia-Aguilar J
Dis Colon Rectum; 2005 Dec; 48(12):2249-57. PubMed ID: 16400512
[TBL] [Abstract][Full Text] [Related]
8. Quality assurance in rectal cancer treatment.
van de Velde CJ; van den Broek CB
Dig Dis; 2012; 30 Suppl 2():126-31. PubMed ID: 23207944
[TBL] [Abstract][Full Text] [Related]
9. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Bonnen M; Crane C; Vauthey JN; Skibber J; Delclos ME; Rodriguez-Bigas M; Hoff PM; Lin E; Eng C; Wong A; Janjan NA; Feig BW
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1098-105. PubMed ID: 15519780
[TBL] [Abstract][Full Text] [Related]
10. Intermediate-fraction neoadjuvant radiotherapy for rectal cancer.
Zhan T; Gu J; Li M; Du C
Dis Colon Rectum; 2013 Apr; 56(4):422-32. PubMed ID: 23478609
[TBL] [Abstract][Full Text] [Related]
11. Rectal cancer: review with emphasis on MR imaging.
Beets-Tan RG; Beets GL
Radiology; 2004 Aug; 232(2):335-46. PubMed ID: 15286305
[TBL] [Abstract][Full Text] [Related]
12. Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.
Eriksen MT; Wibe A; Haffner J; Wiig JN;
Dis Colon Rectum; 2007 Feb; 50(2):156-67. PubMed ID: 17180256
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language.
Glynne-Jones R; Mawdsley S; Novell JR
Colorectal Dis; 2006 Nov; 8(9):800-7. PubMed ID: 17032329
[TBL] [Abstract][Full Text] [Related]
14. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.
van Gijn W; Marijnen CA; Nagtegaal ID; Kranenbarg EM; Putter H; Wiggers T; Rutten HJ; Påhlman L; Glimelius B; van de Velde CJ;
Lancet Oncol; 2011 Jun; 12(6):575-82. PubMed ID: 21596621
[TBL] [Abstract][Full Text] [Related]
15. MRI-based treatment of rectal cancer: is prognostication of the recurrence risk solid enough to render radiation redundant?
Sautter-Bihl ML; Hohenberger W; Fietkau R; Roedel C; Schmidberger H; Sauer R
Ann Surg Oncol; 2014 Jan; 21(1):197-204. PubMed ID: 24002537
[TBL] [Abstract][Full Text] [Related]
16. Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer.
Gollins S
Colorectal Dis; 2010 Aug; 12 Suppl 2():2-24. PubMed ID: 20618363
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of circumferential margin involvement in rectal adenocarcinoma treated with preoperative chemoradiotherapy and low anterior resection.
Luna-Pérez P; Bustos-Cholico E; Alvarado I; Maffuz A; Rodríguez-Ramírez S; Gutiérrez de la Barrera M; Labastida S
J Surg Oncol; 2005 Apr; 90(1):20-5. PubMed ID: 15786412
[TBL] [Abstract][Full Text] [Related]
19. Management and imaging of low rectal carcinoma.
Salerno G; Daniels I; Heald RJ; Brown G; Moran BJ
Surg Oncol; 2004; 13(2-3):55-61. PubMed ID: 15572087
[TBL] [Abstract][Full Text] [Related]
20. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial.
Kusters M; Marijnen CA; van de Velde CJ; Rutten HJ; Lahaye MJ; Kim JH; Beets-Tan RG; Beets GL
Eur J Surg Oncol; 2010 May; 36(5):470-6. PubMed ID: 20096534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
